Oncology drove the day's most significant news in health and biotech small-caps, with EDX Medical Group (AIM:EDX) landing a UK service agreement with global firm Astron Health and Physiomics adding a new oncology engagement to a string of contract wins. Vulcan Two Group rounded out the session with a senior hire aimed at steering its rapidly consolidated ePharmacy platform.
EDX Medical wins UK molecular profiling deal with Astron Health
EDX Medical Group (AIM:EDX) has secured a UK service agreement with global oncology firm Astron Health, under which it will supply two Caris-branded tumour profiling tests. The contract marks a meaningful commercial step for EDX, positioning its molecular diagnostics capability within an established international oncology network. The shares rose 9.1% to 9.0p on the announcement.
Vulcan Two appoints industry veteran as Chief Pharmacy Officer
Vulcan Two Group (AIM:VUL) has named Declan Lismore as Chief Pharmacy Officer, bringing in an industry veteran to oversee dispensing operations, compliance and regulatory relations. The appointment comes as the AIM-listed ePharmacy consolidator works to integrate three acquisitions completed earlier in the year, and signals a focus on operational discipline as the group scales. Michael Kraftman remains part of the leadership structure. The shares eased 1.45% to 272.0p.
Physiomics secures new oncology and biometrics contracts
Physiomics (AIM:PYC) has won a combination of follow-on biometrics engagements and a new oncology contract with a Boston-based biotech, extending its reach across two service lines simultaneously. The AIM-listed modelling and biostatistics specialist, led by Jesse Thissen, continues to build recurring revenue from its computational drug development platform. The shares slipped 2.1% to 0.465p.
